Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
Combinatorial treatments using Etomoxir and Orlistat resulted in synergistic decreased viability in LNCaP, VCaP and patient-derived benign and prostate cancer cells. These effects were associated with decreased androgen receptor expression, decreased mammalian target of rapamycin signaling and increased caspase-3 activation. [Mol Cancer Ther] Abstract
Down-Modulation of Bcl-2 Sensitizes PTEN-Mutated Prostate Cancer Cells to Starvation and Taxanes
Researchers assessed the sensitivity of different prostate cancer cell lines to starvation and observed a differential response correlated to the levels of Akt activation. The four prostate cancer cell lines also showed different sensitivity to taxol treatments; LNCaP and 22Rv1 cells were more resistant to paclitaxel than DU145 and PC3 cells. [Prostate] Abstract
Cancer Research UK Launches Scheme to Bring Together Engineers, Physicists and Biologists
A new funding scheme launched by Cancer Research UK looks to bring new insight to some of cancer’s biggest challenges. The Cancer Research UK Multidisciplinary Project Award will fund projects that encourage collaborations between cancer researchers and scientists from the engineering and physical sciences. [Cancer Research UK] Press Release
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Prostate Cell News? Click here to submit!